Belzutifan, a targeted inhibitor of the HIF signaling pathway that blocks HIF-2alpha [139], was initially studied in patients with renal cell carcinoma (RCC) and non-renal cell neoplasms, including PanNETs, associated with VHL disease [140]. The gene discussed is EPAS1; the disease is renal cell carcinoma.